Over 4.2 Million Americans use blood thinning medication, amounting to several billion dollars every year, with those numbers growing annually. The need for blood thinning medication ranges from short term post-operative medication to ongoing chronic medication.
As with most billion dollar medications, some of the largest global pharmaceutical companies compete for a share of the market, bringing their own branded product into this lucrative market. This is the exact case for a drug known as Xarelto approved in 2011, generic name rivaroxaban, a blood thinning medication manufactured by Bayer and marketed in the U.S. by Johnson and Johnson’s subsidiary, Janssen Pharmaceuticals. A medication that is alleged to cause uncontrolled bleeding, for which there is no antidote.
Complainants, who have filed lawsuits against Bayer, claim that the large profits being made are more important to the company than the lethal side effects inflicting the drugs users. There are currently more than 4500 cases consolidated in federal multidistrict litigation before Judge Eldon E. Fallon in Louisiana under MDL-2592, these numbers exclude the numerous cases filed in state courts.
The main complaint against Xarelto is that it causes uncontrolled bleeding to which there is no antidote, resulting in medical fees, emergency medical attention and death. This is unlike the well known drug warfarin which has been on the market for over 50 years, which is counteracted by Vitamin K to prevent excessive bleeding. In comparison, warfarin users are required to attend regular medical check-ups and blood tests, making it a potentially more expensive route than choosing a drug such as Xarelto.
Despite the high numbers of Xarelto Lawsuits, it has been argued that Bayer continues to not provide sufficient warnings of side effects experienced, and has not yet recalled the sale of Xarelto.
If you or your loved ones have experienced adverse side effects from Xarelto, it is recommended that you join the current lawsuit to add your grievance to the already long list.